Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study

Table 3 Multivariate analysis of each endpoint

Factor		OS			LC			PFS
Factor		HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Age (years)	< 66 vs ≥ 66				0.99	(0.97–1.02)	0.69
Initial T-category	T1–2 vs T3–4	1.57	(0.86–2.83)	0.14
Initial N-category	N negative vs N positive	1.33	(0.69–2.53)	0.39
DFI (months)	< 8.5 vs ≥ 8.5	0.99	(0.99–1.01)	0.11				0.59	(0.39–0.90)	0.01
Radiation therapy method	3DCRT vs IMRT&SBRT				0.95	(0.46–1.97)	0.89
Extra-regional LN for primary site	no vs yes	0.87	(0.45–1.67)	0.67
Number of LN	1 vs 2–5	0.48	(0.27–0.87)	0.02	0.56	(0.30–1.03)	0.06	0.71	(0.47–1.08)	0.11
LN size (cm)	< 2 vs ≥ 2				1.52	(0.83–2.80)	0.18
EQD2 (Gy)	< 60 vs ≥ 60	0.97	(0.95–1.01)	0.09	0.93	(0.90–0.96)	< 0.001

HR hazard ratio, CI confidence interval, OS overall survival rate, LC local control rate, PFS progression-free survival rate, DFI disease-free interval, 3DCRT 3-dimentional conformal radiation therapy, IMRT intensity-modulated radiation therapy, SBRT Stereotactic Body Radiation Therapy, LN lymph node, EQD2 equivalent dose in 2 Gy fraction

ISSN: 1471-2407